Literature DB >> 24642659

Systemic inflammatory reaction after pneumococcal vaccine: a case series.

Kelley A von Elten1, Laurie L Duran2, Taylor A Banks1, Taylor A Banks1, Limone C Collins2, Limone C Collins2.   

Abstract

BACKGROUND: Fever, leukocytosis, and large local reactions following the pneumococcal polysaccharide vaccine (PS23) have been described only in isolated case reports in the adult literature. Such atypical reactions can pose difficulty to providers when determining management. Patients experiencing this noninfectious reaction may receive unnecessary treatment if the diagnosis of robust inflammatory response to the PS23 vaccine is not considered. OBSERVATIONS: This is a clinical case series of 5 adult patients who received the influenza and PS23 vaccines and experienced a cellulitis-like reaction, fever, and leukocytosis in the days following vaccination. Four of the five patients received the influenza and PS23 vaccines in the same arm. The patient who received the vaccines in opposite arms had the local findings in the arm that received the PS23 vaccine. All 5 patients sought care and 4 were admitted to the hospital for observation or treatment with intravenous antibiotics.
CONCLUSIONS: This case series highlights potential side effects of the PS23 vaccine that are not well described in the adult literature. Antibiotics were not helpful in treating these patients' local and systemic symptoms. Patients with histories consistent with that highlighted in this case series may avoid antibiotics and hospitalization if their providers recognize these symptoms as a noninfectious reaction to the PS23 vaccine.

Entities:  

Keywords:  local vaccine reaction; pneumococcal polysaccharide vaccine; systemic inflammatory vaccine reaction

Mesh:

Substances:

Year:  2014        PMID: 24642659      PMCID: PMC5396240          DOI: 10.4161/hv.28559

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  10 in total

1.  Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-04-04

2.  Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-06-01       Impact factor: 17.586

3.  Severe febrile systemic reaction to pneumococcal vaccine.

Authors:  Syed Hasan; Mahmoud Yousef; Sachin Shridharani
Journal:  J Natl Med Assoc       Date:  2005-02       Impact factor: 1.798

4.  Severe protracted fever following pneumococcal vaccine.

Authors:  Arnold Lee; Rishi Goyal; Hui Yi Shan
Journal:  Am J Med Sci       Date:  2006-12       Impact factor: 2.378

5.  Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-09-03       Impact factor: 17.586

6.  Systemic reaction to pneumococcal vaccine: how common in pediatrics?

Authors:  Ejaz Yousef; Susan Mannan
Journal:  Allergy Asthma Proc       Date:  2008 Jul-Aug       Impact factor: 2.587

7.  Acute febrile systemic reaction to polyvalent pneumococcal vaccine.

Authors:  E P Gabor; M Seeman
Journal:  JAMA       Date:  1979-11-16       Impact factor: 56.272

8.  Protracted fever with cellulitis-like reaction in pneumococcal polysaccharide-vaccinated children.

Authors:  Daniel Tsung-Ning Huang; Nan-Chang Chiu; Hsin Chi; Fu-Yuan Huang
Journal:  Pediatr Infect Dis J       Date:  2008-10       Impact factor: 2.129

9.  [Leukemoid reaction and fever after polyvalent polysaccharide pneumococcal vaccination].

Authors:  Vicens Diaz-Brito; Maria Helena Gomes; Paulo Figueiredo-Dias; António Mota-Miranda
Journal:  Acta Med Port       Date:  2007-07-02

10.  Safety of revaccination with pneumococcal polysaccharide vaccine.

Authors:  L A Jackson; P Benson; V P Sneller; J C Butler; R S Thompson; R T Chen; L S Lewis; G Carlone; F DeStefano; P Holder; T Lezhava; W W Williams
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

  10 in total
  5 in total

1.  Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project.

Authors:  Rulin C Hechter; Lei Qian; Sara Y Tartof; Lina S Sy; Nicola P Klein; Eric Weintraub; Cheryl Mercado; Allison Naleway; Huong Q McLean; Steven J Jacobsen
Journal:  Vaccine       Date:  2019-05-04       Impact factor: 3.641

2.  Noninvasive vaccination as a casus belli to redeem vaccine value in the face of anti-vaccine movements.

Authors:  De-Chu C Tang
Journal:  Integr Mol Med       Date:  2017-07-24

3.  Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea.

Authors:  Min-Kyung Kim; Yeon Kyeong Lee; Tae Eun Kim; Insik Kong; Hyeon-Jong Yang; Eun Sook Suh
Journal:  Clin Exp Vaccine Res       Date:  2017-07-26

4.  Immune system correlates of extensive limb swelling in response to conjugated pneumococcal vaccination.

Authors:  Mike Recher; Julia R Hirsiger; Marc B Bigler; Martin Iff; Barbara Lemaître; Kathrin Scherer; Peter Häusermann; Claire-Anne Siegrist; Christoph T Berger
Journal:  NPJ Vaccines       Date:  2018-05-18       Impact factor: 7.344

5.  Possible cytokine biomarkers in pediatric acute appendicitis.

Authors:  Nikola Stankovic; Maja Surbatovic; Ivan Stanojevic; Radoje Simić; Slavisa Djuricic; Maja Milickovic; Blagoje Grujic; Djordje Savic; Vesna Milojkovic Marinovic; Miona Stankovic; Danilo Vojvodic
Journal:  Ital J Pediatr       Date:  2019-10-15       Impact factor: 2.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.